Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) has been granted a marketing authorisation by the European Medicines Agency (EMA) for the treatme 7 March 2022
The European pharma industry has responded to a “non-legislative resolution” detailing plans and actions to move away from using animals in medical research. 7 March 2022
First-in-class lupus therapy Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for people with moderate to severe disease. 16 February 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.